Literature DB >> 26453338

The Clinical Features of Myositis-Associated Autoantibodies: a Review.

Harsha Gunawardena1.   

Abstract

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.

Entities:  

Keywords:  Autoantibodies; Dermatomyositis; Interstitial lung disease; Myopathy; Polymyositis; Systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 26453338     DOI: 10.1007/s12016-015-8513-8

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  129 in total

1.  Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias.

Authors:  Kizuku Watanabe; Tomohiro Handa; Kiminobu Tanizawa; Yuji Hosono; Yoshio Taguchi; Satoshi Noma; Yoichiro Kobashi; Takeshi Kubo; Kensaku Aihara; Kazuo Chin; Sonoko Nagai; Tsuneyo Mimori; Michiaki Mishima
Journal:  Respir Med       Date:  2011-04-22       Impact factor: 3.415

2.  Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.

Authors:  I Marie; S Dominique; A Janvresse; H Levesque; J-F Menard
Journal:  Respir Med       Date:  2012-01-24       Impact factor: 3.415

3.  Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.

Authors:  Manabu Fujimoto; Yasuhito Hamaguchi; Kenzo Kaji; Takashi Matsushita; Yuki Ichimura; Masanari Kodera; Naoko Ishiguro; Ikuko Ueda-Hayakawa; Yoshihide Asano; Fumihide Ogawa; Keita Fujikawa; Takuya Miyagi; Eriko Mabuchi; Kenji Hirose; Narihiro Akimoto; Naohito Hatta; Kiyohiro Tsutsui; Akira Higashi; Atsuyuki Igarashi; Mariko Seishima; Minoru Hasegawa; Kazuhiko Takehara
Journal:  Arthritis Rheum       Date:  2012-02

4.  Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?

Authors:  Jean-Christophe Lega; Vincent Cottin; Nicole Fabien; Françoise Thivolet-Béjui; Jean-François Cordier
Journal:  J Rheumatol       Date:  2010-03-15       Impact factor: 4.666

Review 5.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

6.  Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Takashi Satoh; Masataka Kuwana; Yasuhiro Katsumata; Kae Takagi; Ikuko Masuda; Akiko Tochimoto; Sayumi Baba; Yuko Okamoto; Yuko Ota; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-05-23       Impact factor: 7.580

7.  Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.

Authors:  Kerry B Stone; Chester V Oddis; Noreen Fertig; Yasuhiro Katsumata; Mary Lucas; Molly Vogt; Robyn Domsic; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2007-09

8.  Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rheumatol       Date:  2012-12-19       Impact factor: 2.980

9.  Outcome of anti-PL12 positive patients with antisynthetase syndrome.

Authors:  Isabelle Marie; Séverine Josse; Olivier Decaux; Stéphane Dominique; Cédric Landron; Pascal Roblot; Stéphane Jouneau; Olivier Vittecoq; Fabienne Jouen
Journal:  Presse Med       Date:  2013-02-18       Impact factor: 1.228

10.  Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.

Authors:  Julie D'Aoust; Marie Hudson; Solène Tatibouet; James Wick; Michael Mahler; Murray Baron; Marvin J Fritzler
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

View more
  21 in total

1.  Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin.

Authors:  Lori W Lee; Neera S Narang; Anna Postolova; Nicole Seminara; Molly A Kantor
Journal:  J Gen Intern Med       Date:  2016-12       Impact factor: 5.128

Review 2.  [Inflammatory myopathies].

Authors:  Britta Maurer
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

3.  An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breast cancer.

Authors:  Timothy D Reynolds; Vivek Mohan; Matthew Roy; Nathan Manghat; Huzaifa Adamali; Harsha Gunawardena
Journal:  Eur J Rheumatol       Date:  2017-10-25

Review 4.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

5.  Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.

Authors:  Angela Ceribelli; Natasa Isailovic; Maria De Santis; Elena Generali; Micaela Fredi; Ilaria Cavazzana; Franco Franceschini; Luca Cantarini; Minoru Satoh; Carlo Selmi
Journal:  Clin Rheumatol       Date:  2016-10-20       Impact factor: 2.980

Review 6.  Arthritis in Idiopathic Inflammatory Myopathies.

Authors:  Martin Klein; Heřman Mann; Jiří Vencovský
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 7.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

Review 8.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

9.  Texture analysis of muscle MRI: machine learning-based classifications in idiopathic inflammatory myopathies.

Authors:  Keita Nagawa; Masashi Suzuki; Yuuya Yamamoto; Kaiji Inoue; Eito Kozawa; Toshihide Mimura; Koichiro Nakamura; Makoto Nagata; Mamoru Niitsu
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

10.  Real world utilization of the myositis autoantibody panel.

Authors:  Mithu Maheswaranathan; Andrew Johannemann; Jason J Weiner; Ryan Jessee; Amanda M Eudy; Lisa Criscione-Schreiber
Journal:  Clin Rheumatol       Date:  2021-02-24       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.